Vinorelbine Found to be Effective Secondary Option for Mesothelioma Patients

Those mesothelioma patients that have already undergone a chemotherapeutic course course of pemetrexed may gain benefits from undergoing a second course with a different medication known as vinorelbine. Though Pemetrexed and a platinum-based medication called cisplatin are the most traditional first-line course of chemotherapy treatment used in mesothelioma patients, physicians have found that the use

Healthy Mesothelioma Patients Don’t Benefit From Surgery

A study presented at the 15th World Conference on Lung Cancer has provided controversial information. It indicates that when the patients who are deemed healthiest among mesothelioma victims undergo surgery, it does not provide an appreciable improvement in the patient’s survival rates. The study was conducted in Italy and included data from almost 1,400 patients

Quality of Life Key Consideration for Mesothelioma Patients

A recent study conducted by scientists at Papworth Hospital in Cambridge, United Kingdom,indicated that an invasive keyhole surgery called video-assisted thoracoscopic surgery, or VATS, does nothing to extend mesothelioma patients’ survival rates but does make a considerable improvement in their quality of life. The study was presented at the 15th World Conference on Lung Cancer. 

The Discovery Process in Mesothelioma Lawsuits

Though every mesothelioma lawsuit is different, attorneys follow a standard process to ensure the best possible outcome.  One of the most important phases of litigation is discovery. This pre-trial period involves the gathering and exchange of information between all parties. A thorough discovery process can make all the difference in whether your case settles out

How Artificial Intelligence Is Changing Mesothelioma Care

Artificial Intelligence is revolutionizing many aspects of life, including how doctors approach mesothelioma diagnosis, treatment, and patient care. Advanced computational technologies are improving diagnostic accuracy, speeding up investigational processes, and personalizing treatment approaches. From predicting patient outcomes to discovering novel therapies, AI is transforming mesothelioma care in ways that were unimaginable just a few years ago and

Pembrolizumab-Lenvatinib Combination Delivers 60% Response Rate in Mesothelioma Patients

Mesothelioma patients whose disease progressed after receiving a first-line treatment of nivolumab plus ipilimumab achieved a 60 percent objective response rate when treated with second-line pembrolizumab plus lenvatinib therapy. Dutch researchers report that twenty patients experienced a median progression-free survival of 6.9 months and disease control rates of 90 percent at 3 months and 52.6

Get Help Contacting Mesothelioma.net
This field is for validation purposes and should be left unchanged.
24/7 Live Chat
Online Now